Form 4: Dyne Therapeutics Director Receives Stock Option Grant

Director David Charles Lubner was granted 35,152 stock options in Dyne Therapeutics, Inc. on June 5, 2026.

Summary

• Director David Charles Lubner received a grant of 35,152 stock options.
• The options have an exercise price of $17.04 per share.
• The grant date for these options is June 5, 2026.
• The options are scheduled to vest in full on the earlier of June 5, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to continued service, which could be impacted by future changes in board composition.

Future Outlook

The options vest in one year, aligning the director's tenure with the company's performance through the 2027 Annual Meeting.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure long-term commitment and alignment with shareholder interests.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation packages for mid-cap biotechnology firms.
• The one-year vesting schedule is typical for annual director equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 5, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Dyne Therapeutics, DYN, Form 4, Insider Trading, Stock Options, Director Compensation